News

Royalty Pharma raises 2025 portfolio receipts guidance to $3.05B-$3.15B as integrated company advances biotech funding model
Discover Q2 2025 highlights from Royalty Pharma (RPRX): double-digit growth, raised guidance, a $2B partnership, efficient cost structure, & ...
Barchart on MSN11h
S&P Futures Gain With Focus on Earnings and Fed Speak
Mini futures (ESU25) are trending up +0.24% this morning as investors digested U.S. President Donald Trump’s latest tariff threats and weak economic data, with the focus now shifting to a fresh batch ...